Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.

The potential for reproductive toxicity of an antisense oligonucleotide designed to inhibit ICAM-1 was evaluated as part of the safety assessment for this compound. Since antisense compounds are often specific to the species in which they are intended to work, both the human and murine active ICAM-1 inhibitors were tested (ISIS 2302 and ISIS 3082, respectively). Male and female mice were treated prior to cohabitation, through cohabitation, gestation, delivery, and weaning. Mice were treated with 0, 3, 6, and 12 mg/kg ISIS 2302 or ISIS 3082 by daily i.v. injection. Reproductive indices evaluated included estrus cycling, sperm count and motility, fertility, litter parameters, fetal development, delivery, fetal body weight, lactation, and weaning. Behavioral assessment and reproductive capacity of the F1 generation mice was assessed on selected animals. Concentrations of oligonucleotide in selected maternal target organs, placenta, fetal tissues, and expressed milk were also measured. There were no changes in reproductive performance, litter parameters, fetal development, or postnatal development in mice treated with either ISIS 2302 or ISIS 3082. Maternal liver and kidney contained dose-dependent concentrations of oligonucleotide, but there was relatively little or no oligonucleotide measured in placenta, fetal tissues, or expressed milk. Neither the human nor murine-specific antisense inhibitor of ICAM-1 produced any reproductive toxicity in mice, and exposure of fetus or pups was negligible.

[1]  E. Salewski,et al.  Färbemethode zum makroskopischen Nachweis von Implantationsstellen am Uterus der Ratte , 1964, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[2]  A. Levin,et al.  Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits. , 2004, Birth defects research. Part B, Developmental and reproductive toxicology.

[3]  C. Teng,et al.  Antisense Oligonucleotide-based Therapeutics , 2003 .

[4]  B. Gazzard,et al.  Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. , 2002, American journal of ophthalmology.

[5]  S. Crooke,et al.  Antisense: Progress Towards Gene-Directed Cancer Therapy , 2002 .

[6]  Rosie Yu,et al.  Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis , 2000, Nature Biotechnology.

[7]  S. Agrawal,et al.  Antisense therapeutics: is it as simple as complementary base recognition? , 2000, Molecular medicine today.

[8]  S. Crooke,et al.  Molecular mechanisms of action of antisense drugs. , 1999, Biochimica et biophysica acta.

[9]  Lois E. H. Smith,et al.  Oligonucleotide-based inhibition of embryonic gene expression , 1999, Nature Biotechnology.

[10]  A. Levin,et al.  Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[11]  W. Novotny,et al.  Inhibition of coagulation by a phosphorothioate oligonucleotide. , 1997, Antisense & nucleic acid drug development.

[12]  A. Levin,et al.  Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. , 1997, Antisense & nucleic acid drug development.

[13]  P. Nicklin,et al.  Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. , 1997, Biochemical pharmacology.

[14]  S. Crooke,et al.  Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. , 1997, Anti-cancer drug design.

[15]  D. Kornbrust,et al.  Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. , 1997, Toxicology.

[16]  A. Krieg,et al.  Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. , 1996, Antisense & nucleic acid drug development.

[17]  S. Agrawal,et al.  Pharmacokinetics of Antisense Oligonucleotides , 1995, Clinical pharmacokinetics.

[18]  V. Metelev,et al.  Effect on embryos of injection of phosphorothioate-modified oligonucleotides into pregnant mice. , 1993, Antisense research and development.

[19]  S. Beaucage,et al.  Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach , 1992 .

[20]  S. Agrawal,et al.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Haseman,et al.  Selection of appropriate experimental units in teratology , 1974 .

[22]  Staples Re,et al.  REFINEMENTS IN RAPID CLEARING TECHNIC IN THE KOH-ALIZARIN RED S METHOD FOR FETAL BONE. , 1964 .